AtriCure (ATRC) Tops Q4 EPS by 13c

AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.08), $0.13 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $46.1 million versus the consensus estimate of $45.36 million.

2018 Financial Guidance

Management projects 2018 revenue of approximately $190 million to $196 million. Adjusted EBITDA, a non-GAAP measure, is projected to be positive for 2018.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Amprius Technologies, Inc. (AMPX) Reports In-Line Q1 EPS; offers guidance
• Travere Therapeutics (TVTX) Misses Q2 EPS by 2c
• eXp World Holdings, Inc. (AGNT) Misses Q2 EPS by 9c; offers guidance